Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Amprenavir
Drug ID BADD_D00136
Description Amprenavir is a protease inhibitor used to treat HIV infection.
Indications and Usage For the treatment of HIV-1 infection in combination with other antiretroviral agents.
Marketing Status approved; investigational
ATC Code J05AE05
DrugBank ID DB00701
KEGG ID D00894
MeSH ID C095108
PubChem ID 65016
TTD Drug ID D0A0OO
NDC Product Code Not Available
UNII 5S0W860XNR
Synonyms amprenavir | tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate | (3S-(3R*(1R*,2S*)))-(3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate | VX 478 | VX-478 | Vertex VX478 | Agenerase
Chemical Information
Molecular Formula C25H35N3O6S
CAS Registry Number 161814-49-9
SMILES CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insulin resistance05.06.02.003; 14.06.02.003---
Liver function test abnormal13.03.04.030---
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myositis15.05.01.001--
Nausea07.01.07.001--
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.001---
Neutropenia01.02.03.004---
Opportunistic infection11.01.08.007---
Paraesthesia17.02.06.005; 23.03.03.094--
Pruritus23.03.12.001--
Rash23.03.13.001---
Rhabdomyolysis15.05.05.002--
Skin disorder23.03.03.007---
Sleep disorder19.02.04.001---
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Tremor17.01.06.002--
Vomiting07.01.07.003--
Fat redistribution14.08.04.002---
Lipodystrophy acquired14.08.04.008; 23.07.01.003---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Musculoskeletal discomfort15.03.04.001---
Transaminases increased13.03.04.036---
Paraesthesia oral07.05.05.035; 17.02.06.008---
Abdominal symptom07.01.06.007---
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Inflammation08.01.05.007; 10.02.01.089---
Malnutrition14.03.02.004---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene